HUB International recently issued a sobering forecast: prescription drug costs are expected to climb 10–12% in 2026. This is more than the predicted 9% increase from Business Group on Health. For employers already managing rising health care spend, this projection underscores what many benefit leaders already know, which is pharmacy spend is the fastest-growing and least predictable category of health benefits.
This trend hits more than the bottom line. It has the potential to disrupt the workforce, productivity, and member well-being. Employers are in a tough spot trying to balance cost containment with employee satisfaction. The wrong move risks eroding trust, adherence, and health outcomes.
It’s not all bad news though. There are proven strategies that can deliver meaningful pharmacy savings without disruption to care. But acting early is critical.
Why Drug Costs Are Rising
The drivers behind pharmacy inflation are complex, but four factors stand out:
GLP-1 Use Explosion
Popular diabetes drugs, like semaglutide and tirzepatide, have rapidly taken over the weight management market. Goldman Sachs projected that GLP-1 medications could reach $100 billion in annual sales globally by 2030. Employers have already seen sharp increases in utilization, with some plans reporting double-digit percentage of members requesting these therapies.
Specialty Drugs Overwhelming Spend
Specialty medications now account for over 50% of total pharmacy spend despite serving fewer than 2% of members (IQVIA, 2024). Oncology, autoimmune disorders, and rare disease treatments drive this imbalance. With pipeline drugs continuing to focus on high-cost biologics and gene therapies, specialty spend will only grow.
Mental Health and Chronic Disease Growth
Prescriptions of antidepressants, ADHD medications, and anti-anxiety treatments are still climbing since COVID, especially among younger populations. Chronic conditions with high price tags like cardiovascular disease and diabetes remain prevalent, with more complex, polypharmacy treatment regimens adding to cost and risk.
Inflationary Pressures
Like every sector, pharma is not immune to rising labor, supply chain, and R&D costs. This contributes to list price increases across the board—costs that eventually filter down to plan sponsors and members.
The Impact on Employers and Members
In the past, when pharmacy spend surges, employers relied on blunt instruments to contain costs like:
- Restrictive formularies that limit member choice.
- Step therapy and prior authorization that create administrative burden.
- Higher cost-sharing that shifts financial risk to members.
While these tactics aim to cut costs, they often backfire. According to the Kaiser Family Foundation, almost a third of Americans report that they have trouble affording their prescriptions. When employer-sponsored plans shift more costs onto members, the result can be increased non-adherence, driving downstream medical costs when members skip or abandon treatment.
The result is a lose-lose scenario where plan sponsors absorb higher total costs and employees experience worse health outcomes.
The RazorMetrics Path
Employers need solutions that reduce pharmacy spend without compromising member health or physician autonomy. That is where RazorMetrics comes in.
Our physician-directed solution gives prescribers the information they need to help members save money at the pharmacy. Unlike blunt cost-shifting tactics, our approach engages prescribers directly in their normal workflow, ensuring that every recommendation is clinically appropriate and physician-approved.
How it Works
- Data-driven analysis identifies opportunities for safe, lower-cost therapeutic alternatives.
- Physicians are engaged directly within their usual workflow with no extra clicks, no disruptive real-time benefit tools.
- Physicians decide whether to approve or decline the recommendation.
- If approved, members are seamlessly transitioned to lower-cost medications. This process respects the physician-patient relationship while producing measurable savings.
Across clients, including Fortune 500 employers, municipalities, and health plans, RazorMetrics has consistently demonstrated:
- High physician acceptance rates, proving that recommendations are clinically sound.
- Member savings through reduced out-of-pocket costs.
- Plan sponsor savings in the millions annually, directly reducing trend.
- Improved adherence by lowering the financial barrier to treatment.
The Road Ahead: Preparing for 2026
The pharmacy cost storm is not a distant threat, it’s arriving in less than 4 months. HUB International’s forecast of double-digit drug trend increases for 2026 should be a wake-up call. Employers who wait until costs spike will find themselves with fewer options and more pressure to shift costs to employees.
Instead, forward-thinking employers are moving now to:
- Adopt biosimilars where clinically appropriate.
- Address polypharmacy to reduce unnecessary prescriptions.
- Deploy physician-directed switching for therapeutic alternatives.
By taking action now, employers can ease the burden of 2026’s projected increases and demonstrate to their workforce that they are committed to affordability and health outcomes.
Start now: Employers that act will be better prepared to weather the storm ahead.
